{1-[2-(2-Methoxy-phenoxy)-ethyl]-1H-benzoimidazol-2-ylsulfanyl}-acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: {1-[2-(2-Methoxy-phenoxy)-ethyl]-1H-benzoimidazol-2-ylsulfanyl}-acetic acid
• 英文别名: 2-[1-[2-(2-methoxyphenoxy)ethyl]benzimidazol-2-yl]sulfanylacetic acid
• 化学式: C₁₈H₁₈N₂O₄S
• mdl: MFCD01128212
• 分子量: 358.4
• InChiKey: TWTCEYCXVZNFQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  98.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
  申请人：Texas Tech University System

  公开号：US10463649B2

  公开（公告）日：2019-11-05

  The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.

  本发明包括抑制MCL-1的组合物和方法，包括MCL-1的新型抑制剂，以及治疗对一种或多种MAPK通路蛋白抑制剂难治的癌症患者的组合物和方法。
• Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors
  申请人：Texas Tech University System

  公开号：US20180161313A1

  公开（公告）日：2018-06-14

  The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.